Search Results for: Kimera labs

COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more

February 1, 2021 / By / 3 Comments
cell therapy for COVID

  It’s been a busy week for the cellular and regenerative medicine space for COVID-19 news with some possible ups including for Mesoblast and some definite downs. Starting with the more positive media buzz with have Mesoblast. Mesoblast made COVID19 news “Thinly traded Mesoblast Limited (NASDAQ:MESO) rockets 51% premarket on average volume in reaction to its announcement of an …

COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more Read More »

As clinics buzz about coronavirus, COVID19 patient given non-FDA-approved exosomes?

February 1, 2021 / By / 4 Comments
Kimera-Labs-exosomes-COVID-19-novel-coronavirus-disease

When the number of stem cell clinical studies and trials listed for COVID-19 first started spiraling upward it seemed likely that stem cell clinics and other firms in that arena would get interested. I thought that we’d see the unproven regenerative medicine coronavirus bandwagon quickly grow. Unfortunately, there are reasons to be increasingly concerned here. For instance, …

As clinics buzz about coronavirus, COVID19 patient given non-FDA-approved exosomes? Read More »

As exosome work advances, clinics pitch unproven therapies to patients

February 1, 2021 / By / 29 Comments
exosome-clinical-trials

Time to sell exosome therapies to patients? No. Some stem cell clinics and related firms are looking for new ways to make profits and toward that goal a few have latched onto the legitimate buzz around exosome research. What are exosomes? Imagine if you could bubble up a pea-sized sphere off your skin full of …

As exosome work advances, clinics pitch unproven therapies to patients Read More »

FDA leader Stephen Hahn was pressured to aid Texas firm Direct Biologics

November 23, 2022 / By / 3 Comments
Former FDA Commissioner Stephen Hahn.

An FDA FOIA dump of text messages of former Commissioner Stephen Hahn suggests that a Texas regenerative firm called Direct Biologics benefited from political pressure on him in mid-2020. Then he was asked again to help in early 2021. This was shortly before he resigned at the start of the Biden Administration. The push came from …

FDA leader Stephen Hahn was pressured to aid Texas firm Direct Biologics Read More »

Fact-checking exosome therapy: costs, risks, & lack of data

November 27, 2022 / By / 5 Comments
model of an exosome, exosome therapy

Exosome therapy is a still-experimental cell therapy approach aimed at treating specific diseases using secretions from cells. It’s novel since most attention on cell therapies has been given to using the actual cells themselves. In addition, this approach is a newer idea than using cells as the drug to treat diseases. Interestingly, the term “cell …

Fact-checking exosome therapy: costs, risks, & lack of data Read More »

Grading my 20 stem cell predictions for 2020

February 1, 2021 / By / 1 Comment
Knoepfler-The-Niche-stem-cell-blog-predictions-2020

Each year I metaphorically try to look into a crystal ball for stem cell predictions for the coming year and I did so for 2020, but the COVID-19 pandemic threw a monkey wrench into my predictions. It actually kind of blew some up. It also raised some interesting questions and dilemmas. For instance, do many …

Grading my 20 stem cell predictions for 2020 Read More »

Field throws stem cells for COVID-19 like spaghetti on the wall

February 1, 2021 / By / 12 Comments
Hype

The idea of testing stem cells for COVID-19 may be music to the ears of some folks as an opportunity, but to me from the beginning it sounded mostly like a spaghetti on the wall road to trouble. There is buzz out there that some kind of stem cells or other cells will help with …

Field throws stem cells for COVID-19 like spaghetti on the wall Read More »